Covance and sanofi-aventis finalise r&d alliance

Published: 2-Nov-2010
Finance

Covance also acquires sanofi-aventis plants in France and the UK


Covance has finalised its deal with sanofi-aventis to become the French drugmaker’s research and development partner over the next 10 years.

Covance has also bought sanofi-aventis' Porcheville, France and Alnwick, UK sites and all employees will transfer to Covance.

The deal, announced on 29 September, is expected to generate revenues ranging from US$1.2bn to US$2.2bn over the next decade.

Covance, headquartered in Princeton, New Jersey, US provides drug development services to the pharmaceutical industry.

  • Companies:
  • Covance
  • Sanofi
See more

You may also like

Finance

Sanofi begins negotiations with CD&R to sell stake in Opella

Read more
Opella is currently estimated to be worth €16bn, and CD&R's stake will allow the consumer healthcare company to grow as a standalone business

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. Bringing biotech to the Baltics: the rise of Lithuania Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a still-unsaturated market. Dr Kevin Robinson spoke with the country’s Minister for Economy and Innovation, Aušrinė Armonaitė, to find out more
  3. CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
  4. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development
  5. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Finance

Sanofi begins negotiations with CD&R to sell stake in Opella

Opella is currently estimated to be worth €16bn, and CD&R's stake will allow the consumer healthcare company to grow as a standalone business
Finance

Sanofi finalises Inhibrx acquisition

The acquisition expands Sanofi’s AATD therapeutic pipeline
Drug Delivery

Sanofi pledges to sell over €10bn in vaccine sales

In less than two years, Sanofi has delivered a competitive mRNA platform with improved potency and thermostability that performs with both viral and bacterial targets
Drug Delivery

Sanofi acquires Provention Bio and gains diabetes therapy

Following its acceptance of the tendered shares, Sanofi completed its acquisition of Provention Bio through the merger of a wholly owned subsidiary of Sanofi with and into Provention Bio
Regulatory

Sanofi's ALTUVIIIO approved by the US FDA

"This positive event triggers impairment reversal, positively impacting 2022 IFRS net income"
Manufacturing

Sanofi increases evergreen fund to $750m

The additional capital, confirmed by the executive committee, will also fuel the expansion and investment capacity of the Sanofi Ventures
Finance

Neuraxpharm to increase branded business by acquiring established Sanofi products

Neuraxpharm, the central nervous system (CNS) specialist, to acquire two portfolios of established products for CNS disorders, pain and vascular diseases
Subscribe now